|
1
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chandarlapaty S, Sawai A, Scaltriti M,
Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK,
Baselga J and Rosen N: AKT inhibition relieves feedback suppression
of receptor tyrosine kinase expression and activity. Cancer Cell.
19:58–71. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Faber AC, Li D, Song Y, Liang MC, Yeap BY,
Bronson RT, Lifshits E, Chen Z, Maira SM, García-Echeverría C, et
al: Differential induction of apoptosis in HER2 and EGFR addicted
cancers following PI3K inhibition. Proc Natl Acad Sci USA.
106:19503–19508. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mendoza MC, Er EE and Blenis J: The
Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends
Biochem Sci. 36:320–328. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Turke AB, Song Y, Costa C, Cook R, Arteaga
CL, Asara JM and Engelman JA: MEK inhibition leads to PI3K/AKT
activation by relieving a negative feedback on ERBB receptors.
Cancer Res. 72:3228–3237. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hoeflich KP, Merchant M, Orr C, Chan J,
Den Otter D, Berry L, Kasman I, Koeppen H, Rice K, Yang NY, et al:
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K
inhibitor GDC-0941 triggers robust apoptosis and tumor growth
inhibition. Cancer Res. 72:210–219. 2012. View Article : Google Scholar
|
|
8
|
Sos ML, Fischer S, Ullrich R, Peifer M,
Heuckmann JM, Koker M, Heynck S, Stückrath I, Weiss J, Fischer F,
et al: Identifying genotype-dependent efficacy of single and
combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl
Acad Sci USA. 106:18351–18356. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jokinen E, Laurila N and Koivunen JP:
Alternative dosing of dual PI3K and MEK inhibition in cancer
therapy. BMC Cancer. 12:6122012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bedard P, Tabernero J, Kurzrock R, et al:
A phase lb, open-label, multicenter, dose-escalation study of the
oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2
inhibitor GSK1120212 in patients (pts) with selected advanced solid
tumors. J Clin Oncol (ASC Annual Meeting abstracts).
30:30032012.
|
|
11
|
Britten C, Wainberg Z, Tabernero J, et al:
A multi-arm phase 1 dose escalation study of safety,
pharmacokinetics, and pharmacodynamics of the dual PI3K/mTOR
inhibitors PF-04691502 (oral) and PF-05212384 (IV) in combination
with the MEK inhibitor PD-0325901 or irinotecan in patients with
advanced cancer. Eur J Cancer. 48:1092012. View Article : Google Scholar
|
|
12
|
LoRusso P, Shapiro G, Pandya SS, et al: A
first-in-human phase 1b study to evaluate the MEK inhibitor
GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in
patients with advanced solid tumors. J Clin Oncol (ASC Annual
Meeting abstracts). 30:25662012.
|
|
13
|
Faber AC, Coffee EM, Costa C, Dastur A,
Ebi H, Hata AN, Yeo AT, Edelman EJ, Song Y, Tam AT, et al: mTOR
inhibition specifically sensitizes colorectal cancers with KRAS or
BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.
Cancer Discov. 4:42–52. 2014. View Article : Google Scholar :
|
|
14
|
Hata AN, Yeo A, Faber AC, Lifshits E, Chen
Z, Cheng KA, Walton Z, Sarosiek KA, Letai A, Heist RS, et al:
Failure to induce apoptosis via BCL-2 family proteins underlies
lack of efficacy of combined MEK and PI3K inhibitors for
KRAS-mutant lung cancers. Cancer Res. 74:3146–3156. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Youle RJ and Strasser A: The BCL-2 protein
family: Opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View
Article : Google Scholar
|
|
16
|
Morelli MP, Tentler JJ, Kulikowski GN, Tan
AC, Bradshaw-Pierce EL, Pitts TM, Brown AM, Nallapareddy S,
Arcaroli JJ, Serkova NJ, et al: Preclinical activity of the
rational combination of selumetinib (AZD6244) in combination with
vorinostat in KRAS-mutant colorectal cancer models. Clin Cancer
Res. 18:1051–1062. 2012. View Article : Google Scholar
|
|
17
|
Wee S, Jagani Z, Xiang KX, Loo A, Dorsch
M, Yao YM, Sellers WR, Lengauer C and Stegmeier F: PI3K pathway
activation mediates resistance to MEK inhibitors in KRAS mutant
cancers. Cancer Res. 69:4286–4293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ellis L, Ku SY, Ramakrishnan S, Lasorsa E,
Azabdaftari G, Godoy A and Pili R: Combinatorial antitumor effect
of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten
defecient model of prostate cancer. Oncotarget. 4:2225–2236.
2013.PubMed/NCBI
|
|
19
|
He L, Torres-Lockhart K, Forster N,
Ramakrishnan S, Greninger P, Garnett MJ, McDermott U, Rothenberg
SM, Benes CH and Ellisen LW: Mcl-1 and FBW7 control a dominant
survival pathway underlying HDAC and Bcl-2 inhibitor synergy in
squamous cell carcinoma. Cancer Discov. 3:324–337. 2013. View Article : Google Scholar : PubMed/NCBI
|
